Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.50M | $26.82M | $14.24M | N/A | N/A | $117.91M | $94.39M | $43.01M |
| Cost of Revenue | $4.17M | $9.50M | $1.70M | $18.78M | $18.77M | $1.32M | $1.40M | $292.68M |
| Gross Profit | $32.33M | $17.32M | $12.54M | $-18.78M | $-18.77M | $116.59M | $92.99M | $-249.67M |
| Gross Margin | 88.59% | 64.57% | 88.03% | 0.00% | 0.00% | 98.88% | 98.52% | -580.48% |
| Operating Expenses | $458.07M | $408.81M | $401.58M | $359.64M | $317.14M | $542.93M | $455.47M | $71.12M |
| Operating Income | $-425.74M | $-391.49M | $-389.05M | $-378.42M | $-335.92M | $-426.33M | $-362.48M | $-320.79M |
| Operating Margin | -1166.47% | -1459.52% | -2732.07% | 0.00% | 0.00% | -361.57% | -384.03% | -745.84% |
| Net Income | $673.73M | $-352.09M | $-231.80M | $1.60B | $-327.37M | $-411.47M | $-346.03M | $-314.67M |
| Net Margin | 1845.92% | -1312.63% | -1627.82% | 0.00% | 0.00% | -348.97% | -366.61% | -731.60% |
| EPS (Basic) | $11.86 | $-6.33 | $-4.23 | $-6.36 | $-4.74 | $-6.61 | $-6.03 | $-6.75 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |